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The recently published KDIGO (Kidney Disease: Improvement
of Global Outcomes) guideline (GL) for dialysate calcium
suggests a narrow range of dialysate inlet calcium
concentrations (CdiCa
þþ ) of 2.50–3.00mEq/l. The work
group’s primary arguments supporting the GL were (1) there
is a negligible flux of body Caþþ during dialysis and (2)
CdiCa
þþ of 2.50mEq/l will generally result in neutral Caþþ
mass balance (CaMB). We believe we have shown that both of
these arguments are incorrect. Kinetic modeling and analysis
of dialyzer Caþþ transport during dialysis (JdCa
þþ )
demonstrates that more than 500mg of Ca can be
transferred during a single dialysis and that on average 76%
of this Ca flux is from the miscible calcium pool rather than
plasma pool. Kinetic modeling of intestinal calcium
absorption (CaAbs) shows a strong dependence of CaAbs on
the dose of vitamin D analogs and weaker dependence on
the level of Ca intake (CaINT). We used the CaAbs model to
calculate CaAbs as a function of total CaINT and prescribed
doses of vitamin D analogs in 320 hemodialysis patients. We
then calculated total dialyzer calcium removal (TJdCa
þþ )
and the CdiCa
þþ that would be required to achieve
TJdCa
þþ ¼CaAbs, that is, CaMB¼ 0 over the whole dialysis
cycle (that is, covering both the intra- and the inter-dialytic
period). The results indicate that 70% of patients on Ca-based
binders and 20–50% of patients on non-Ca-based binders
would require CdiCa
þþ o2.50mEq/l to prevent long-term
Ca accumulation.
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Patients undergoing hemodialysis (HD) frequently develop
widespread medial arterial calcification, which is strongly
associated with adverse cardiovascular outcomes and is
widely considered to be associated with excess body content
of calcium (Ca) and phosphorus (P).1–4 Despite numerous
large scale multinational studies of mineral abnormalities in
HD, there are no consensus guidelines for the integrated
prescription of dietary Ca and P, choice of phosphate binders,
dialysate Ca, vitamin D analogs and calcimimetics to HD
patients. Optimal management of mineral metabolism in HD
patients should include consideration of the effects of the
total therapeutic regimen on Ca and P mass balance (CaMB,
PMB) in addition to changes in serum Ca and P, bone
histology and parathyroid hormone. None of the many
studies of Ca-based vs non-Ca-based phosphate binders have
included consideration of CaMB with respect to prescribed
dialysate inlet Ca (CdiCa
þþ ), the dose of vitamin D analogs
and Ca intake (CaINT).
THE KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES
(KDIGO) CLINICAL PRACTICE GUIDELINE FOR THE DIAGNOSIS,
EVALUATION, PREVENTION, AND TREATMENT OF CHRONIC
KIDNEY DISEASE – MINERAL AND BONE DISORDER
A comprehensive set of guidelines for management of
mineral and bone disorders in chronic kidney disease
(CKD-MBD) has been developed by KDIGO and recently
published.5 Overall these guidelines provide valuable and
comprehensive recommendations for the management of
CKD-MBD based on clinical evidence, expert opinion and
clinical experience. However, guideline 4.1.3.5 (‘In patients
with CKD stage 5D, we suggest using a dialysate calcium
concentration between 1.25 and 1.50mmol/l (2.50 and
3.00mEq/l) (2D)’) is based on clinical opinion and appears
to be unduly restrictive and likely to result in positive CaMB
in a substantial fraction of HD patients. The two key
arguments the work group advanced in support of this
guideline were
(1) ‘The percentage of body calcium that is dialyzable is very
small’ and
(2) ‘The work group felt that, in general, a dialysate
concentration of 1.25mM/l (2.50mEq/l) would be a
near-neutral Ca balance for most patients’.
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We have reported6 that large quantities of body Ca can be
removed or accumulated by diffusive transport across the
dialyzer during dialysis, which contradicts the first argument.
The second argument addresses Ca mass balance (CaMB) only
during dialysis and thus contains the implicit assumption
that CaMB between dialyses is zero and that none of the
ingested diet and binder Ca are absorbed. We have reported
analyses of Ca absorption (CaAbs) as a function of CaINT and
levels of calcitriol7,8 indicating that substantial amounts of
CaINT are absorbed with modern vitamin D analog therapy.
Thus both of the work group arguments supporting a lower
limit of CdiCa
þþ ¼ 2.50mEq/l appear invalid to us.
MODELED DIFFUSIVE DIALYZER Caþþ FLUX AND
INTRADIALYTIC DIFFUSIVE Ca MASS BALANCE
The primary reference for the first argument mentioned
above was a study reported by Hou and colleagues,9 in which
they studied three 4-h high flux dialyses on six patients with
dialysate inlet calcium (CdiCa
þþ ) levels of 1.50, 2.25 and
3.50mEq/l. Plasma total Ca (CpiCaT) was measured every
30min and spent dialysate was collected every 30min for
measurement of total Ca and phosphorus (P). The work
group concluded from this paper that the amount of body Ca
dialyzable is very small despite the fact that with the low
CdiCa
þþ the average removal of Caþþ was 230mg with
minimal change in CpiCa
þþ and with the high CdiCa
þþ
there was accumulation of 800mg Caþþ with negligible
change in plasma Caþþ . Mathematical analysis of these data
led us to conclude that it was a classic data set shedding the
first light on the kinetics of the dialyzer–patient interaction
during diffusive Caþþ flux in HD. We modeled these data as
depicted schematically in Figure 1. We calculated the
magnitudes (mg) of diffusive dialyzer Caþþ transport
(SJDiffCa
þþ ) and the accumulation of Caþþ in extracellular
water (DCpiCa
þþ VECW) every 30min from the reported
data. As illustrated in Figure 1 the total uptake of Ca from
dialysate, SJDiffCa
þþ , was much greater than the accumula-
tion of Ca in extracellular water, DCpiCa
þþ VECW, which
led us to the mathematical prediction of a large Caþþ buffer
pool in rapid diffusion equilibrium with VECW from which
Caþþ could be mobilized (MþCaþþ ) or in which it could
be sequestered (M-Caþþ ) and thus support plasma
concentration when there is substantial diffusive flux during
dialysis. As depicted, the magnitude of buffering in the pool
(MCaþþ ) was calculated as the total amount of Caþþ
accumulated in VECW, DCpiCa
þþ VECW minus the total
diffusive flux SJDiffCa
þþ in accordance with
SMCaþþ¼DCpiCaþþ  VECW SJDiffCaþþ ð1Þ
The relationships in Equation (1) are very helpful to
predict the change in CpiCa
þþ , which can be expected
(which is discussed below) with high levels of diffusive
flux during dialysis. It is important to emphasize that
Equation (1) defines diffusive dialyzer flux relative to
diffusive Ca mass balance in ECW (CaMBDECW) whereas
intradialytic total body Ca mass balance (CaMBT) is always
defined only by total intradialytic dialyzer diffusive plus
convective flux as defined below. As the parathyroid glands
respond primarily to changes in plasma Caþþ concentra-
tion, the magnitude of CaMBD might be expected to relate
quantitatively to the magnitude of stimulation and/or
inhibition of parathyroid secretion during dialysis with
diffusive Caþþ flux and thus be an important parameter
of the patient–dialyzer interaction to define.
The analysis reported is further illustrated in Figure 2a
where the constant level of CdiCa
þþ and 30-min CpiCa
þþ
values are plotted and show the large diffusive flux gradient
persisting throughout dialysis with CdiCa
þþ 3.50mEq/l.
The reported mathematical solution of the mass balance rate
equations for MCaþþ is also shown as well as
the sequestration (M-Caþþ ) of 700mg. In Figure 2b the
calculated values for (DCpiCa
þþ VECWSMCaþþ ) vs
measured SJDiffCa
þþ are shown for all three of the Hou
data sets plus a similar analysis done on data reported
by Nolph 40 years ago10 in a CAPD patient with vitamin D
intoxication treated with CAPD dialyses extended over
several days. Note that very large amounts of body Caþþ
can be mobilized from or sequestered in the buffer pool
during dialysis with substantial diffusive dialyzer calcium
transport.
THE CALCIUM BUFFER POOL
This entity, which we predicted from mathematical analysis
of SJDiffCa
þþ and diffusive Ca mass balance in ECW
(DCpiCa
þþ VECW) was actually shown to be the miscible
calcium pool (MCP) on bone surfaces and partially
quantified 30 years earlier in the paper ‘Model of Short-
Term Regulation of Calcium-Ion Concentration’ by Jaros,
Coleman and Guyton in the journal Simulation.11 They
reported blood flow to the MCP of 250ml/min and a surface
area of amorphous calcium phosphate crystals of approxi-
mately two acres, which are in rapid exchange equilibrium
with ECW. The arterial flow to the MCP is in parallel to the
arterial flow to the dialyzer and approximately ½ of the
dialyzer blood flow. If the blood entering the MCP has an
abnormally high or low Ca concentration, the concentration
of Ca in blood returning to the venous circulation has been
shown to have normal concentration (11), which indicates an
MCP clearance of Ca that is virtually infinite and can readily
effect flux equal to and opposite in sign to dialyzer flux.
This has been thought to be a simple physicochemically
driven transport but this will have to be verified over time.
In our clinical experience to date with dialysate of Ca
2.00mEq/l we have not observed increases in parathyroid
hormone over time (unpublished observations) but a larger
data base will be required to rigorously determine what
role parathyroid hormone might have in mobilization of
Ca from the MCP and what effect cinacalcet might have on
this flux.
We have further quantified the buffer capacity of the
MCP12,13 and derived an MCP buffer coefficient (KMP),
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Figure 1 | Illustration of intradialytic flux analyses that led to mathematical prediction of a large calcium buffer pool supporting
plasma calcium concentration during diffusive dialyzer calcium flux.
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Figure 2 |The magnitude of buffering of change in plasma Caþþ by the calcium buffer pool. (a) Depicts the analysis of the Hou data9
with CdiCa
þþ 3.50mEq/l described further in the text. (b) Depicts the close relationship of modeled to measured Caþþ flux in the Hou and
Nolph data10 discussed further in the text.
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which can be used to assess and predict the buffering
magnitude of SJDiffCa
þþ . The KMP is defined as
KMP ¼ SMCa
þþ
SMCaþþ þ DCpiCaþþ  VECW ð2Þ
where the quantities must be expressed in absolute
units because the sign of SMCaþþ is the opposite of
DCpiCa
þþ VECW. Examination of Equation (2) shows that,
if DCpiCa
þþ VECW¼ 0, all SJDiffCaþþ is buffered in the
MCP and the KMP will equal 1.00. If on the other hand,
SMCaþþ ¼ 0 and SJDiffCaþþ ¼DCpiCaþþ VECW, the
KMP¼ 0 so the KMP can range from 0 to 1.00. In studies at
the Renal Research Institute (RRI), New York, we have
determined KMP from serial measurements of Ca levels at the
dialyzer inlet (CdiCa
þþ ) and outlet (CdoCa
þþ ) every 10min
and CpiCa
þþ measured thrice during dialysis in 30 patients
receiving high flux dialysis therapy using NOVA 8 ISE and, as
described previously8 estimation of VECWat the end of dialysis as
1/3 of the mean kinetic urea distribution volume. The results of
these measurements are shown, along with two values calculated
from the Hou data, in Figure 3. The observed KMP¼ 0.76±0.10
(M±s.d., n¼ 30) over a range of SJDiffCaþþ 500 to
þ 800mg/dialysis. These data show that at least 500mg Caþþ
can be removed during dialysis and on average 76% will be
mobilized from the miscible calcium pool so it can be calculated
that with removal of 500mg the plasma Caþþ will fall
approximately 0.25mmol/l (0.5mEq/l; 1mg/dl).13
MODELED ABSORPTION OF DIETARY AND BINDER CALCIUM
IN CURRENT DIALYSIS THERAPY
We have derived and reported a kinetic model of CaAbs in
HD patients as a function of CaINT and therapy with vitamin
D analogs.6–8,12,13 The model was derived from kinetic
modeling of data reported in a series of single meal calcium
absorption studies at Baylor University in the late 1980s14–16
and further validated recently from 1-week balance studies
with sevelamer and CaCO3.
17 The generalized modeling
equations derived for CaAbs were
12
CaAbs ¼ ð16:64  Lnð36  DoseD32OHÞ þ 19:5Þ  LnðCaINTÞ
 38:5  Lnð36  DoseD32OHÞ  216
ð3Þ
and
CaAbs ¼ ð16:64  Lnð4:5  dose paricalcitol or doxercalciferolÞ
þ19:5Þ  LnðCaINTÞ
38:5  Lnð4:5  dose paricalcitol or doxercalciferolÞ216
ð4Þ
where D32OH is the dose of calcitriol (mg/dialysis); paricalci-
tol and doxercalciferol are expressed in mg/dialysis, and CaINT
in mg/day.
We recently conducted a cross sectional survey of 320
Fresenius Medical Care North America (FMC) HD patients
treated with calcium acetate (Ca(Ac)2) as phosphate binder.
12
Diet recall was used to assess dietary CaINT and the CaAbs
modeling equations were used to calculate CaAbs from CaINT
and prescribed doses of vitamin D analogs. The results of the
survey are shown in Figure 4a where values for the individual
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Figure 4 |Calcium absorption as a function of CaINT and dose
of vitamin D analogs. In (a) the points calculated for 320
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is also depicted. In (b) cumulative frequency curves of CaAbs for
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patients are plotted on the CaAbs model grid. CaINT from diet
only is shown as open circles and CaINT from the sum of diet
and Ca(Ac)2 is shown as closed circles. CaINT from diet in the
data set averaged 350mg/day whereas total CaINT averaged
1600mg/day. The mean dose of vitamin D analog was 4 mg/
dialysis but it can be seen to range from 0 to 16 mg/dialysis
(95% of doses). The shaded bar labeled 800 in Figure 4a
represents the level of CaINT recommended recently by Moe
and Chertow18 and is shown for comparative purposes.
In Figure 4b three cumulative frequency distributions for
CaAbs are plotted. Curve 1 is the frequency distribution of the
values observed for total CaINT and vitamin D analog doses in
the Figure 4a data set. Curve 2 is the frequency distribution of
CaAbs calculated for the distribution of the vitamin D analogs in
Figure 4a with the assumption that CaINT ¼ 800mg/day.18
Curve 3 is the frequency distribution with the observed values
for diet CaINT of 350mg/day only and the vitamin D analog
doses in the data base. Curve 1 obviously represents CaAbs
observed with current Ca(Ac)2 therapy. Curves 2 and 3 can be
considered to represent simulations of CaAbs with non-Ca-
based binders such as sevelamer and lanthanum carbonate and
at 2 levels of dietary Ca intake. The median values for calculated
CaAbs are 160, 110 and 80mg/day, but CaAbs varies widely for
all three curves due to the wide range in doses of vitamin D
analogs prescribed and the wide range of Ca intake (curve 1).
CALCULATION OF CdiCa
þþ REQUIRED TO ACHIEVE NEUTRAL
CaMB IN HD THERAPY
CaMB is defined as
CalciumMass Balance ¼
Calcium Input fromDiet and Binders
 CalciumRemoval by Dialysis
ð5Þ
Examination of Equation (5) shows that to satisfy the
requirement that CaMB¼ 0 we must be able to show that
Calcium Input fromDiet and Binders ¼
CalciumRemoval duringDialysis
ð6Þ
CaAbs has been defined above inEquations (3) and (4) so
we must now define Caþþ removal. Instantaneous Ca flux
(JdCa
þþ , mEq/min or mg/min) during dialysis is deter-
mined by: (1) the ionized Caþþ concentration gradient
between plasma inlet (CpiCa
þþ ) and dialysate inlet
(CdiCa
þþ ) of the dialyzer, that is, (CdiCa
þþCpiCaþþ ),
mEq/l; (2) the dialysance of Caþþ (DCaþþ , l/min); and (3)
the product of the ultrafiltration rate (Qf) and CpiCa
þþ .
These parameters can be combined into an expression for
instantaneous dialyzer solute transport12
JdCa
þþ¼DCaþþ  ð1:12  CdiCaþþCpiCaþþÞ
 ð1Qf=QeÞQf  CpiCaþþ ð7Þ
where 1.12 is a Donnan coefficient; Qf is ultrafiltration rate,
l/min; Qe is the effective solute diffusion volume flow
rate, l/min.
Although only the diffusible fraction of plasma Caþþ is
dialyzable, protein bound Ca dissociates very rapidly so the
effective driving force for diffusion is total inlet plasma Ca
(CpiCaT).
12,19,20 This effective plasma Ca content, which is
approximately twice the ionized content, results in calculated
dialysance values substantially greater than plasma flow rate
and hence KoA (overall dialyzer permeability-area product
coefficient) values cannot be calculated, because the calcula-
tion is discontinuous when DCa4Qp and results in an
undefine Ln. The KoA is a critically important parameter for
kinetic modeling because it permits calculation of DCaþþ for
any combination of dialysate flow (Qd), Qe and Qf. We
derived a generalized expression to calculate KoACaþþ by
defining the effective flow rate for Caþþ (Qe) as twice the
plasma flow rate and confirmed this from mass balance
between blood and dialysate compartments.20 We found that
the KoA was dependent also on flow rate (r¼ 0.62, n¼ 30,
P¼ 0.02) in accordance with
KoACaþþ¼ 332  LnðQeÞ  1409 ð8Þ
All of the terms in Equation (7) are constants except
CpiCa
þþ . To use this expression for modeling calcium
removal over a complete dialysis we must know the mean
value of CpiCa
þþ or MCpiCa
þþ in Equation (7). With-
Equations (3) or (4), respectively, the required or prescribed
JDiffCa (RxJdCa
þþ ) can be calculated, and from the relation-
ships above between JdCa
þþ and KMP (Equaions (1) and (2))
we can compute the expected DCpiCa
þþ in accordance with
DCpiCaþþ¼ ðRxJdCa  ð1KMPÞÞ=VECW ð9Þ
From a measured predialysis Cp0Ca
þþ and calculated
DCpiCa
þþ a value for end dialysis CpiCa
þþ can be readily
calculated as
CptCa
þþ ¼CpoCaþþDCpiCaþþ ð10Þ
We have determined in ongoing clinical studies (unpub-
lished) that CpiCa
þþ approaches the CptCa
þþ value asymp-
totically and integration of the mean value function yields
MCpiCa
þþ ¼CptCaþþ  ððCp0Caþþ CptCaþþÞ=0:012  tdÞ
 ðexp ð0:012  tdÞ  1Þ ð11Þ
Equation (7) is re-written here as (7b) to now show clearly
how we can use this expression to calculate CdiCa
þþ
required for neutral CaMB as follows:
X
JdCa
þþ ¼ ½DCaþþ  ð1:12  CdiCaþþ MCpiCaþþÞ
 ð1Qf=QeÞQf M CpiCaþþ  td
ð7bÞ
where MCpiCa
þþ is the mean CpiCa
þþ (mEq/l). Note that
Equation (7) is multiplied above by dialysis time (td) and
represents total JdCa
þþ during each dialysis. CaAbs can be
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calculated for any set of CaINT and vitamin D analog dosing
coordinates. Neutral CaMB over the week requires that the
weekly CaAbs must be removed during the total number (N)
of dialyses prescribed per week, usually 3. So we can now
substitute (CaAbs  7)/N for JdCaþþ in Equation (7) above
and solve for CdiCa
þþ in accordance with
CdiCa
þþ ¼
7  ðCaAbsÞ=N þQf M CpiCaþþ þDCaþþ M CpiCaþþð1Qf=QeÞ
1:12  DCaþþ
ð12Þ
MODELED CdiCa
þþ DISTRIBUTIONS FOR CALCIUM-BASED
AND NON-CALCIUM-BASED PHOSPHATE BINDERS IN HD
THERAPY
The three frequency distributions for CaAbs in Figure 4b were
used to calculate frequency distributions for CdiCa
þþ
required to achieve a neutral CaMB with the distribution of
vitamin D analog doses seen in Figure 4a. The dialyzer
parameters typical for high flux dialysis were used and
consisted of Qe 0.4 l/min, DCaþþ 0.2 l/min, td 210min, Qf
0.012 l/min. The results are shown in Figure 5 where the three
cumulative frequency distributions are compared to the
KDIGO guideline calling for CdiCa
þþ 2.50–3.00mEq/l.
Curve 1 represents the data set for patients treated
with Ca(Ac)2 plotted in Figure 4a. With the minimum
CdiCa
þþ ¼ 2.50mEq/l in the guideline, 70% of these
patients are predicted to be in positive CaMB. The median
CdiCa
þþ required for this group is 2.25mEq/l, below the
lower bound of the guideline. Curve 2 represents a simulated
patient group with constant CaINT 800mg/day
18 and use of a
non-calcium-based binder such as sevelamer with the
distribution of vitamin D analog prescriptions depicted in
Figure 4a. In this case 50% of the patients are predicted to be
in positive CaMB and the median CdiCa
þþ is 2.50 at the
lower bound of the guideline. Curve 3 represents a simulated
patient group with CaINT we observed for diet only in Figure
4a and assuming binder therapy is with a non-Ca-containing
binder and the vitamin D analog prescriptions shown in
Figure 4a. In this case 80% of the required CdiCa
þþ for the
simulated therapy falls within the guideline with the median
CdiCa
þþ of 2.75mEq/l in the middle of the guideline
domain. This series of calculations indicates that the KDIGO
guideline for CdiCa
þþ is suitable for only a small subset of
patients with low dietary Ca intake and treated with low
doses of Vit D analogs.
IMPLICATIONS OF CALCIUM KINETIC MODELING FOR CLIN-
ICAL STUDIES OF P BINDERS IN HD
Doses of vitamin D analogs and CdiCa
þþ are usually not
reported in studies of Ca-based and non-Ca-based P binders
and are never adjusted to achieve equal CaMB in both arms of
studies comparing these two classes of binders. We believe
these are binder study design flaws with consequences
illustrated in Figure 6. Panel A depicts typical coordinates
for CaINT and CaAbs that might be seen in a study comparing
Sevelamer and Ca(Ac)2. With the dose of paricalcitol chosen
for this illustration (6mg/dialysis), the CaAbs would increase
from about 100 to 200mg/day when patient is switched to
Ca(Ac)2. Panel B depicts generalized solution of Equation
(12) for CdiCa
þþ required to achieve neutral CaMB with the
family of CaAbs curves shown in panel 6A. The simulated data
points for sevelamer and Ca(Ac)2 in panel A can be seen in
panel B to show that neutral CaMB would require CdiCa
þþ
levels of 2.3 and 2.0mEq/l, respectively, for the sevelamer and
Ca(Ac)2 study periods. In addition, the vertical pink arrows in
panel B depict the predictable large changes in CaMB, which
will occur if vitamin D analog doses are changed for any
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and compared to the KDIGO guideline for CdiCa
þþ . Note that on curves 1 (Ca(Ac)2) and 2 (Diet CaINT 800mg/day only) 70 and 50% of
patients, respectively, will have calcium accumulation with CdiCa
þþ 2.50mEq/l. On curve 3, with tightly controlled dietary Ca intake only
20% of patients are predicted to be in positive CaMB and about 15% will have negative CaMB with a maximal CdiCa
þþ of 3.00mEq/l.
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reason during either study interval and will be unrecognized if
the doses of Vit D3 analogs are not reported for the study.
CONCLUSIONS AND RECOMMENDATIONS
The KDIGO guideline for dialysate calcium was based on
clinical opinion and did not include any quantitative assess-
ments of dialyzer calcium and phosphorus transport, calcium
absorption as a function of Ca intake and vitamin D analog
therapy or calcium mass balance. Quantitative analysis of
calcium mass balance strongly indicates that the dialysate
calcium guideline will result in Ca accumulation in many
patients, which could contribute significantly to the high
incidence of coronary artery calcification in these patients. The
major KDIGO work group research recommendations were for
large sample size clinical outcome studies comparing the various
types of phosphate binders. We believe quantitative control of
CaAbs with calcium kinetic modeling, which was not considered
by the work group for the studies proposed, is mandatory in
binder studies to avoid unmeasured and unrecognized bias.
The work group did not mention a need for studies of
dialyzer Ca and P transport or studies of Ca absorption with
the doses of modern Vit D analogs now prescribed. Virtually
all of the studies in kinetic modeling of mineral metabolism
in HD over the past 8 years have been done by our group at
the Renal Research Institute in New York. We believe this
work has added important new insights into mineral
metabolism in HD therapy but there is need for expansion
and further confirmation of these studies by other investigators.
This has been a neglected but very important area of research,
which is likely to have a major impact on the management and
outcome of CKD-MBD and the associated very high incidence
of coronary artery disease. We believe it is time for new
paradigms for both research and therapy in this field.
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